India, May 5 -- Biocon Biologics (BBL), subsidiary of Biocon, today announced the Company has secured multiple market access agreements for Yesintek' (ustekinumab-kfce), its biosimilar to Stelara' (ustekinumab). The market access agreements from numerous plans represent over 100+ million lives in the United State.Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025. Cigna has added YESINTEK to its commercial formulary beginning on March 21, 2025. UnitedHealthcare has added YESINTEK to several formularies including commercial beginning May 1, 2025; managed Medicaid beginning March 1, 2025; and Medicare beginning June 1, 2025. CVS Health has added YESINTEK beginning July 1, 2025. And finally, O...